Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Oncology Rx Pricing Focus Shifts To Medicaid: House Cmte. Seeks Documents

Executive Summary

The passage of AWP reform in Medicare will not end Congressional scrutiny of the oncologic drug market
Advertisement

Related Content

Medicaid Reform Next On Health Care Agenda: GAO To Assess Rebates
Medicaid Reform Next On Health Care Agenda: GAO To Assess Rebates
Chain Drug Medicaid Pricing Records Sought By House Committee
Chain Drug Medicaid Pricing Records Sought By House Committee
Medicaid Best Price Reform: Dual-Eligible Move To Medicare May Be 1st Step
Centocor Marketing Practices Under Investigation By U.S. Attorney
Chemotherapy Overuse May Be Encouraged By Medicare AWP System - Tauzin
HCFA Reform, Drug Pricing Protections Urged Prior To Medicare Expansion
Congressional Drug Pricing Investigation Receives Boost From Rep. Bliley
Congressional Drug Pricing Investigation Receives Boost From Rep. Bliley
Advertisement
UsernamePublicRestriction

Register

PS042057

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel